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Acetonitrile (HPLC grade) and benzene were dried for 24 h on thermally-activated molecular 
sieves (3Å, sieve activation by 24 h heating at 315°C).. Unless stated otherwise, all reactions 
were performed with unpurified, undried, non-degassed solvents and analytical grade 
reagents, used as obtained, under a protective atmosphere of argon. Yields were optimized for 
compound 1 and the synthesis was started from dissymmetric dptacn (Stavila, V., et al. 
(2008). New J Chem, 32, 428–435). All compounds are characterized by 1H-NMR spectra 
(see annex below). All spectra were acquired on a Bruker AVANCE (500 MHz) as indicated, 
at 293 K. All HPLC analyses of complexes reported below were executed using the following 
chromatographic conditions: column : Zorbax Eclipse XDB-C8, 3.5 µm, 3.5 x 150 mm. 
Mobile phase: isocratic 20% A and 80% B; A = 0.10 mM ammonium formate in water; B = 
acetonitrile. Flow Rate: 0.45 mL/min. Column temp. : 25°C 
Unit mass measurements were performed on an “AGILENT 1100 SL” LCMS system with 
direct injection of the sample in ESI mode.  




A single-necked flask (50 mL) containing a solution of 0.8 g of freshly synthesized dptacn (?) 
in benzene (25 mL) is treated with 0.38 g (1.5 eq) of p-nitrobenzaldehyde and 0.145 mL (1.5 
eq) of 1,2,3-triazol. A Dean-Stark apparatus with an additional narrow siphon installed below 
the habitual barrier between the flask neck and the reservoir is placed on the flask before the 
contents are refluxed for 18 h. The mixture is placed under argon and cooled to room 
temperature. An anhydrous acetonitrile solution of ([Fe(BF4)2 6 MeCN] is now added in a 
titration-like manner, and the formation of complex 1 monitored by LCMS. The resulting 
solution is stirred for another 15 min. before being filtered over dry paper filter. The filtrate is 
concentrated under vacuum and the residue dissolved in a minimal volume of water/MeCN 
(95/5 v/v). This solution is applied to a reversed-phase cartridge (C18; 20 mL of immobile 
phase) that has been pre-conditionned with two cartridge volumes of MeCN followed by two 
volumes of water. After elution with pure water (250 mL) a gradient of water / MeCN (99/1 
to 90/10, v/v) is applied that results in the collection of several intensely red fractions. These 
fractions are analysed by LCMS and the ones corresponding to 1 united. Evaporation of the 
solvents yields a red resin that is taken up in MeCN and recrystallized by ether diffusion at 
4°C in pyrex tubes (50 mL). After several days burgundy-red crystals are harvested to yield 
0.55 g (29 %) of a micro-crystalline powder. 




Starting material N-(4-Formylphenyl)-2-phenylacetamide was synthesized according to a 
literature procedure in high yields (S. A. Nunez et al., J. Org. Chem. 2011, 76, 10099−10113). 
3 
0.21 g (19%) of red powder, compound was purified to homogeneity by RP chromatography 
on a C18 cartridge.  
 
Complex 5: [Iron(II) (1-((4-nitrophenyl)(1H-pyrazol-1-yl)methyl)-4,7-bis(pyridin-2-
ylmethyl)-1,4,7-triazacyclononane] (BF4)2 
0.110 (9%) of burgundy-red crystals. 
 
Complex 6: [Iron(II) ((1-((4-phenylacetamidophenyl)(1H-pyrazol-1-yl)methyl)-4,7-
bis(pyridin-2-ylmethyl)-1,4,7-triazacyclononane)] (BF4)2 .  
0.163 g (12%) of burgundy-red crystals. Here, wet, commercial quality of Fe(BF4)26H2O 
sufficed. 
 
Complex 7: [Iron(II) (1-((4-nitrophenyl)(1H-1,2,3-benzotriazol-1-yl)methyl)-4,7-bis(pyridin-
2-ylmethyl)-1,4,7-triazacyclononane] (BF4)2 




Structural Analyses by X-ray diffraction 
Figure S1 : Grown crystals of ferrous complex 1 
  
Figure S2 : X-ray structural analysis of 1 
(macrocycle and picolyl hydrogens omitted for clarity) 
 
Summary of data CCDC 902789 
Formula: C31 H33 B2 F8 Fe1 N9 O2 
Unit cell parameters: a 10.599(2) b 16.1450(10) c 20.264(2) 
beta 100.520(10) 




Figure S3 : Grown crystals of ferrous complex 5. 
Crystals grown by diethylether diffusion into acetonitrile solution; macrocycle and picolyl 
hydrogens omitted for clarity. 
  
Figure S4 : X-ray structural analysis of 5 
(macrocycle and picolyl hydrogens omitted for clarity) 
 
Summary of data CCDC 902790 
Formula: C31 H30 B2 F8 Fe1 N9 O2 
Unit cell parameters: a 9.1444(6) b 10.5370(7) c 20.1930(10) 
alpha 78.459(5) beta 89.809(5) gamma 66.744(6) 




Figure S5 : Grown crystals of ferrous complex 6 
 
Figure S6 : X-ray structural analysis of 6 
(macrocycle and picolyl hydrogens omitted for clarity) 
 
Summary of data CCDC 902791 
Formula: C32 H38 Cl2 Fe1 N10 O10 
Unit cell parameters: a 12.7583(7) b 12.7820(8) c 13.7071(6) 
alpha 65.170(5) beta 76.373(4) gamma 61.484(6) 




Mass spectral characterization of complexes 1, 2, 5, 6, and 7. 














[M]2+ : m/z = 284.6;
[M + Cl]+ : m/z = 604.1
[M + HCOO]+ : m/z = 614.2
[M + HCO3]+ :m/z = 630.2
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[M]2+ : m/z = 328.8;
[M + Cl]+ : m/z = 692.2
[M + HCOO]+ : m/z = 702.2
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Mass analysis complex 6 (dissolved powder): 
 
  
[M]2+ : m/z = 328.3;
[M + HO]+ : m/z = 673.3
[M + F]+ : m/z = 675.3
[M + Cl]+ : m/z = 692.3
[M + HCOO]+ : m/z = 702.3
[M + HCO3]+ : m/z = 717.3
[M + BF4]













Mass analysis complex 7 (dissolved crystals): 
 
  
[M]2+ : m/z = 309.75;
[M + F]+ : m/z = 638.5
[M + Cl]+ : m/z = 654.5
[M + HCOO]+ : m/z = 664.5














Mass analysis complex 5 (dissolved crystals): 
 
 
[M]2+ : m/z = 284.2;
[M + HO]+ : m/z = 585.5
[M + Cl]+ : m/z = 603.9
[M + HCOO]+ : m/z = 613.48
[M + HCO3]+ : m/z = 629.5











UV spectra for complexes 1, 5, and 7 (0.02 mM in 50 mM PB). 
Triazol (1):  
Pyrazol (5):  
Benzotriazol (7):  
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Monitoring	   of	   activation	   of	   nitro	   derivatives	   initiated	   by	   hydroge-­‐
nation	  
Typical protocol for initiation by hydrogenation (pH 7.4; 4 mM of 1). 
To a PB (50 mM; 1 mL;) solution of complex 1 (3.0 mg; 4 mM) is added 10 mg Pd/C (5 or 10 
% w/w). Hydrogen gas is bubbled via a needle through the suspension for 5-10 min. before 
total reduction of 1 is confirmed by mass analysis. The solution is then filtered, and the pH of 
7.4 confirmed before being brought to 37°C. At this temperature the already ongoing 
immolation reaction is monitored at regular intervals by mass analysis or T1 measurement. 
Figure S7 : Mass spectral monitoring of activation of 1 (direct injection). 
Mass spectral analysis was carried out by direct injection of a sample into the mass 
spectrometer set to the “scan” and positive ESI modes. The following scheme associates the 






















[M]2+ : m/z = 284.6;
[M + Cl]+ : m/z = 604.0








[M + Cl]+ : m/z = 402.0;












[M]2+ : m/z = 269.6 ;
[M + Cl]+ : m/z = 574.1




t = 5min         t = 15min. 
 














[M]2+ : m/z = 269.73;
[M + HO]+ : m/z = 556.5
[M + Cl]+ : m/z = 574.9













[M + Cl]+ : m/z = 402.7













[M + Cl]+ : m/z = 402.7
[M]2+ : m/z = 269.73;
[M + Cl]+ : m/z = 574.9
[M + HCOO]+ : m/z = 584.5
[M]2+ : m/z = 269.73;
[M + Cl]+ : m/z = 574.9
[M + Cl]+ : m/z = 402.7













[M]2+ : m/z = 269.73;
[M + Cl]+ : m/z = 574.9





















































Figure S9 : HPLC monitoring of activation of 1  

















t = 5 min
t= 30 min
t= 75 min













Mass spectrum by direct injection into mass spectrometer after catalytic hydrogenation for 5 

















[M]2+ : m/z = 269.73;
[M + Cl]+ : m/z = 574.9
[M + HCOO]+ : m/z = 584.5
[M + HCO3]+ : m/z = 600.5
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The following mass spectrum has been obtained by direct injection of the final HPLC sample 
(t = 150 min) into the mass spectrometer so as to be able to observe the signal for compound 4 
and thus demonstrate that the final HPLC chromatogram corresponds truly to total conversion 
to 4 : 
 










Figure S10 : Robustness of 1 demonstrated by HPLC/UV monitoring 
 
Figure S11 : Robustness of 1 demonstrated by mass spectral monitoring (direct 
injection) 






















[M]2+ : m/z = 284.6
[M + Cl]+ : m/z = 604.0
[M + HCOO]+ : m/z = 614.0
[M]2+ : m/z = 284.6
[M + Cl]+ : m/z = 604.0
[M + HCOO]+ : m/z = 614.0
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The peak at retention time 3.8 min and t = 24 h is caused only by the untouched probe 1, as 













[M]2+ : m/z = 284.6
[M + HCOO]+ : m/z = 614.0
21 
Figure S12 : Absence of fragmentation of pyrazol complex 5 (negative control) 
 
22 
Mass spectrum (direct injection) of sample corresponding to HPLC chromatogram above at 
15 hours. Spectrum proves absence of any traces of fragmentation of aniline derivative of 5 













[M]2+ : m/z = 269.2
[M + HCOO]+ : m/z = 583.5
23 
Figure S13 : Mass spectral monitoring of activation of 7 (direct injection) 












[M]2+ : m/z = 294.8;
[M + F]+ : m/z =608.2
[M + HCOO]+ : m/z = 634.5























[M]2+ : m/z = 294.8;
[M + F]+ : m/z =608.2
[M + HCOO]+ : m/z = 634.5























[M]2+ : m/z = 294.8;
[M + F]+ : m/z =608.2
[M + HCOO]+ : m/z = 634.5











t = 180 min 
 
 










[M]2+ : m/z = 294.8;
[M + F]+ : m/z =608.2






















[M]2+ : m/z = 294.8;
[M + F]+ : m/z =608.2
[M + HCOO]+ : m/z = 634.5










Figure S14 : T1 monitoring by MRI (phantom images at 7T) 
Figure 3 (main article) contains parts of the same data.  
The sequence VTR allows the acquisition of multiple T1-weighted MR images with variable 
TR. From this saturation-recuperation sequence, T1 values can be estimated assuming a 
mono-exponential signal recovery. 
t = 20 min.  t = 50 min. 
  







t = 3 h t = 3.5 h 
  
Legend : 
For t = 20, 50, 90 min 
    ISA-1 = positive control, 1 + chemical stimulus 4 mM, image 24 hours later (PBS) 
     ISA-3 = 1 + chemical stimulus 4 mM, t = 20, 50, 90 min after induction 
     ISA-5 = 1 + no chemical stimulus 4 mM, t = 20, 50, 90 min 
     ISA-7 = 2 + PA 4 mM, image 24 hours later 
     ISA-8 = PBS  
For t = 120, 180 min 
                ISA-1 = positive control, 1 + chemical stimulus 4mM, image 24 hours later (PBS) 
     ISA-3 = 1 + chemical stimulus 4 mM, t = 120 and 180 min after induction 
     ISA-5 = 1 + no chemical stimulus 4 mM, t = 120 min and 180 min 
     ISA-7 = 2 + PA 4 mM, image 24 hours later 
     ISA-8 = PBS 
                ISA-9 = 2 + No PA 4 mM, t = 30 min 
For t = 210 min 
     ISA-1 = positive control, 1 + chemical stimulus 4 mM, image 24 hours later (PBS) 
     ISA-3 = 1 + chemical stimulus 4mM, t = 210 min after induction 
     ISA-5 = 1 + no chemical stimulus 4mM, t = 210 min 
     ISA-6 = 2 + no PA 4 mM, t = 110 min 
     ISA-7 = 2 + PA 4 mM, image 24 hours later 
     ISA-8 = PBS 
     ISA-10 = [Gd(ddota)] at 4 mM (commercial source) 
30 





Monitoring	  of	  incubation	  of	  2	  with	  penicillin	  amidase	  PA	  






















Figure S16 : Mass spectral monitoring : 2 / PA 


















[M]2+ : m/z = 328.8;













[M]2+ : m/z = 269.73;
[M + HCOO]+ : m/z = 584.5



























[M]2+ : m/z = 269.73;













[M]2+ : m/z = 328.8;



































[M + HCOO]+ : m/z = 584.5
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Figure S17 : Demonstration of robustness of 2 w/a PA (negative control)  















[M]2+ : m/z = 328.8;
[M + Cl]+ : m/z = 692.6
[M + HCOO]+ : m/z = 702.6
[M + HCO3]+ : m/z = 718.6
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[M]2+ : m/z = 328.8;
[M + Cl]+ : m/z = 692.6
[M + HCOO]+ : m/z = 702.6
[M + HCO3]+ : m/z = 718.6
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[M]2+ : m/z = 328.8;
[M + Cl]+ : m/z = 692.6
[M + HCOO]+ : m/z = 702.6
[M + HCO3]+ : m/z = 718.6
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2: 1H-NMR spectrum (500 MHz, CD3CN) 
































































5: 1H-NMR spectrum (500 MHz, CD3CN) 




























































6: 1H-NMR spectrum (500 MHz, CD3CN) 













































































































































7: 1H-NMR spectrum (500 MHz, CD3CN)  
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